Loading company…
SaNOtize develops nitric oxide-based therapeutics and technologies to address microbial infections.
Founded in 2017 and based in Vancouver, Canada, SaNOtize develops therapeutics using nitric oxide's antimicrobial properties. Its pipeline includes nitric oxide nasal spray and treatments for chronic sinusitis, diabetic foot ulcers, and nail fungus. In August 2022, the company raised USD 24 million in Series B funding co-led by Horizons Ventures and OurCrowd, with participation from ABC International, to expand research and clinical development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in